Trending...
- Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
- Spokane: Impacts For Final Stretch of Construction Season
- Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
Eve Wellness located in SF offers the first FDA-approved ultrasound screening technology specifically designed for detecting cancer in dense breast tissue.
SAN FRANCISCO - Washingtoner -- Eve Wellness, a San Francisco-based breast cancer screening clinic, is leading the charge in breast cancer screening by providing women the opportunity to get screened earlier, at any age, without a doctor referral, using their FDA-Approved GE ABUS ultrasound technology, powered by FDA-Approved AI (artificial intelligence), all without radiation. This comes on the heels of the FDA's new mandate, announced on March 9, 2023, requiring all mammography facilities to report breast density information and enhance communications with patients and providers.
The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."
More on Washingtoner
Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.
"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."
At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.
More on Washingtoner
"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."
Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.
For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.
The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."
More on Washingtoner
- Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
- Tacoma: Community Event Funding Announced for 2027
- New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
- Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
- PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.
"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."
At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.
More on Washingtoner
- Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount
- Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
- Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
- Spokane: Convicted Felon Arrested in Vancouver After Eluding SPD Officers
- Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."
Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.
For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.
Source: Eve Wellness, Inc.
Filed Under: Health, Artificial Intelligence
0 Comments
Latest on Washingtoner
- Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
- Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
- ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
- Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
- Revenue Optics Names Prat Patibandla Director of Growth Marketing
- Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
- JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
- Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
- Cummings Graduate Institute Celebrates New Doctor of Behavioral Health Graduates
- Visit London Appoints The SEO Works for AI-First Search Strategy
- Spokane: Parks & Recreation Secures Top Ranking for $4.6M in State Grant Match
- City of Spokane to Install First 'Emergency Streets' Lane Closure After Weekend Fatal Crash
- Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
- Century Fasteners Corp. Exhibiting at the 2026 International Fastener Expo
- Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
- Tacoma: 'Preparing the Bid' Workshop on October 19
- Tacoma: Street Operations Crew Scheduled to Conduct Snow and Ice Training October 12 – 14
- Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
- Guberman to Business Owners, Implant Patients: Your ISO 9001,ISO 13485 AS9100,AI9100 Certificate Is Dead, and Nobody Knows What's Inside You
- NYC Big Book Award Celebrates 10th Anniversary with Announcement of 2026 Winners
